Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

16.44
-0.1400-0.84%
Post-market: 16.40-0.0400-0.24%19:59 EDT
Volume:2.34M
Turnover:38.28M
Market Cap:1.53B
PE:-104.34
High:16.68
Open:16.65
Low:16.13
Close:16.58
52wk High:21.98
52wk Low:13.70
Shares:93.25M
Float Shares:82.10M
Volume Ratio:0.97
T/O Rate:2.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1576
EPS(LYR):-0.5920
ROE:-6.86%
ROA:-1.99%
PB:8.48
PE(LYR):-27.77

Loading ...

PagerDuty Inc. Appoints Todd McNabb as New Chief Revenue Officer to Drive Global Growth

Reuters
·
Sep 04

PagerDuty Appoints Todd Mcnabb as Chief Revenue Officer

THOMSON REUTERS
·
Sep 04

PagerDuty Inc - on Aug 28 Board Approved $200 Mln Share Repurchase Program - SEC Filing

THOMSON REUTERS
·
Sep 04

PagerDuty Q2 Adj. EPS $0.30 Beats $0.21 Estimate, Sales $123.411M Miss $123.639M Estimate

Benzinga
·
Sep 04

PagerDuty Inc. Reports Q2 Revenue Increase of 6.4% to $123.4 Million, Achieves $0.10 GAAP EPS and $0.30 Non-GAAP EPS

Reuters
·
Sep 04

PagerDuty Announces Second Quarter Fiscal 2026 Financial Results

THOMSON REUTERS
·
Sep 04

PagerDuty Inc: Outlook Q3 Non-Gaap Net Income per Diluted Share $0.24 - $0.25

THOMSON REUTERS
·
Sep 04

PagerDuty Inc: Outlook Q3 Total Revenue $124.0 Mln - $126.0 Mln

THOMSON REUTERS
·
Sep 04

PagerDuty Inc: Outlook FY Total Revenue $493.0 Mln - $497.0 Mln

THOMSON REUTERS
·
Sep 04

PagerDuty Inc: Outlook FY Non-Gaap Net Income per Diluted Share $1.00 - $1.04

THOMSON REUTERS
·
Sep 04

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

GlobeNewswire
·
Sep 03

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

GlobeNewswire
·
Sep 03

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Sep 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 02

Hong Kong Stocks Movement | LEE'S PHARM (00950) Surges Over 21% in Late Trading as H1 Net Profit Grows 7.5%, Subsidiary's PD-L1 Monoclonal Antibody Receives Domestic Approval

Stock News
·
Sep 01

The "Disruptive Therapy" for Cancer: China's Innovative Drug "DeepSeek Moment"! The Core Keyword: PD(L)1 bsAb

Deep News
·
Aug 31

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Aug 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 28

HENLIUS (02696): International Multicenter Phase 2 Clinical Study of Injectable HLX43 (PD-L1 Targeted Antibody-Drug Conjugate) for Advanced Non-Small Cell Lung Cancer Completes First Patient Dosing in the United States

Stock News
·
Aug 22

ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval

Stock News
·
Aug 20